Ipimo

Quick links to important sections

Ipimo

Method of action: Psycholeptics

Treatment option: Schizophrenia

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ipimo

Property Description
Active ingredient Pimozide
Form Oral tablets
Pharmacological class First-Generation Antipsychotic (Neuroleptic)
General purpose Stability in central nervous system function
Origin Synthetic diphenylbutylpiperidine derivative

Ipimo is a prescription-only medication whose active ingredient is Pimozide. It is classified as a First-Generation Antipsychotic (FGA), an older category of agents also referred to as a conventional neuroleptic drug. Designed for oral administration as a single-ingredient agent, Pimozide is a synthetic compound that acts by stabilizing chemical signaling in the central nervous system (CNS), making it a high-potency agent typically reserved for severe symptoms.


What Type of Medicine is Ipimo (Pimozide)?

Ipimo's classification as a First-Generation Antipsychotic is supported by pharmacological studies for its effects on central brain chemistry. Its active component, Pimozide, is a synthetic chemical substance structurally defined as a diphenylbutylpiperidine derivative. This core chemical identity determines its high potency and focused mechanism of action on central brain pathways. Its classification as a potent FGA differentiates it from newer, atypical agents and confirms its established role in managing highly disruptive CNS conditions, such as severe, involuntary motor and vocal tics.


Pimozide: Form and High-Level Function

Pimozide is manufactured as oral tablets, which enables systemic activity throughout the body after being swallowed. The drug's mechanism is fundamentally rooted in its function as a powerful dopamine receptor antagonist. This means Pimozide selectively blocks the activity of dopamine receptors in the brain, helping to moderate or reduce the overactivity of dopaminergic signaling. The general purpose of this action is to achieve chemical stability and control over involuntary physical movements and severely disrupted thought patterns, consistent with its classification as a neuroleptic.

Regulatory References

  1. Pimozide: MedlinePlus Drug Information
  2. Pimozide (Orap) mechanism of action - LiverTox - NCBI Bookshelf (NIH)

What side effects are possible with Ipimo?

Possible Side Effects and Safety Information for Ipimo

Official government regulatory databases and authoritative health agency records do not contain a safety profile or list of approved adverse drug reactions for a specific pharmaceutical product named "Ipimo." This means that an established, officially documented safety monograph for this name is not currently available from major global regulatory bodies, such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

Consequently, there is no official documentation regarding:

  • Key Adverse Reaction Categories: No specific categories (e.g., gastrointestinal, dermatologic, cardiovascular) or frequencies (very common, rare) are documented.
  • Serious Adverse Reactions: No life-threatening or clinically significant reactions are formally listed in regulatory labeling.
  • Population-Specific Safety Considerations: No warnings or specific safety adjustments for populations like pediatric, geriatric, or those with organ impairment are defined under an approved regulatory label for this name.
  • Safety-Related Restrictions: No restrictions regarding co-administration with other substances or use in specific medical conditions are formally published.

Official Safety Structure

Given the lack of a corresponding approved drug product, no formal regulatory frequency framework (like the ICH frequency bands) is applied. The safety understanding is defined by its absence in official records, which serves as the current, fact-checked safety structure for this name. Any information claiming to list side effects for a prescription medicine named Ipimo must be verified against an official, approved regulatory label to ensure accuracy and patient safety. Consult a healthcare professional for verification of any product information.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Ipimo (Pimozide) is considered severe and potentially life-threatening by regulatory authorities due to the high risk of serious cardiovascular and neurological complications. The official prescribing information mandates specific actions and prolonged monitoring.


Documented Overdose Manifestations

Symptoms officially documented in regulatory sources include profound sedation, severe extrapyramidal symptoms (EPS), and hypotension (low blood pressure). The most critical risks are life-threatening ventricular arrhythmias such as Torsade de Pointes and severe QT interval prolongation, which can lead to cardiac arrest and sudden death.


Required Emergency Actions

It is mandatory to seek immediate medical attention for any suspected overdose. Emergency services (911) or the Poison Help line must be called immediately if the affected person has collapsed, had a seizure, has trouble breathing, or can't be awakened, as these represent severe outcomes.


Official Management and Monitoring

No specific antidote is known for Pimozide overdose, meaning management is strictly symptomatic and supportive. Regulatory documents require immediate interventions like gastric lavage and the administration of activated charcoal. Furthermore, due to the drug's long half-life, continuous ECG monitoring in a healthcare setting is mandated for a minimum of four days to monitor for cardiac risks, with immediate correction of any underlying electrolyte imbalances.

Therapeutic Uses of Ipimo

The medication may be part of symptomatic management in therapeutic domains involving severe chronic tic symptoms and certain profound neuropsychiatric manifestations.

The primary use of Ipimo is in managing severe Tourette's Disorder, addressing debilitating motor and phonic tics. It is also considered relevant in specialized contexts, such as certain forms of delusional disorder.

Severe Chronic Motor and Vocal Tics

Ipimo is a specialized medication applied in addressing severe, debilitating motor and phonic tics in patients with Tourette's Disorder. It helps manage symptoms of increased neurological or muscular activity that create noticeable physiological strain and interfere with a patient's stability. This contributes to easing the overall symptom load by supporting the management of the frequency and intensity of these disruptive manifestations.

“Ipimo supports patients during episodes of heightened discomfort by focusing on symptoms that substantially compromise day-to-day functional stability.”

Reserve Treatment for Refractory Symptoms

This medication is commonly used as a second-line therapeutic option for managing severe tics that are refractory—meaning the patient has not responded adequately or cannot tolerate standard first-line treatments. When initial strategies have failed, Ipimo is applied in clinical settings that involve acute or unstable symptom patterns and may be part of symptomatic management for stabilization. It may assist with symptomatic relief, which helps patients cope more steadily with difficult episodes.


Quick Fact: Relief for Severe, Debilitating Tics

Ipimo provides supportive relief for involuntary physical movements and uncontrolled vocalizations that interfere with daily functioning. It may assist with managing symptoms that have been difficult to address with typical therapeutic approaches.

Eligibility and Restrictions for Use

Who Can and Cannot Use Ipimo? (Population Eligibility)

The use of Ipimo (Pimozide) is subject to strict limitations defined by official government regulatory documents based on age and pre-existing medical conditions.

Populations for Whom Use is Contraindicated

Use is prohibited for patients with: congenital long QT syndrome or a history of cardiac arrhythmias; known hypokalemia or hypomagnesemia; severe toxic central nervous system depression or comatose states; depressive disorders; or Parkinson's syndrome. The medicine is also strictly contraindicated for treating tics other than those associated with Tourette's Disorder.

Age-Group Eligibility Rules

Age Group Regulatory Status
Adults and Adolescents (12+ years) Use is established for the approved indication.
Children (Under 12 years) Safety and effectiveness have not been established.
Geriatric Patients (65+ years) Safety and efficacy have not been studied.

Condition-Specific Restrictions

Use is contraindicated in patients with certain liver disorders and renal insufficiency. Additionally, patients identified as poor CYP2D6 metabolizers require a significantly restricted maximum daily dose.

What should I know about interactions with other medicines?

The official regulatory profile for Ipimo (Pimozide) is defined by two primary drug-drug interaction categories that increase the risk of serious heart rhythm problems, including ventricular arrhythmias.

Contraindicated Drug Combinations

Co-administration is strictly contraindicated with the following due to formally documented interaction risks:

  • Strong Inhibitors of CYP3A4 and CYP2D6: These include certain macrolide antibiotics (e.g., clarithromycin, erythromycin), azole antifungal agents (e.g., itraconazole, ketoconazole), protease inhibitors, and specific SSRIs (e.g., sertraline, paroxetine). These pharmacokinetic interactions impede Pimozide's metabolism, leading to toxic systemic concentrations.
  • Drugs that Prolong the QT Interval: This group includes many antiarrhythmic medicines and other neuroleptics. The interaction is classified as pharmacodynamic reinforcement, increasing the likelihood of adverse cardiac events.

Other Documented Interactions

  • Substances that Increase Exposure: The consumption of grapefruit juice must be avoided because it can officially increase Pimozide's plasma levels by inhibiting its metabolic clearance.
  • Central Nervous System Depressants: The risk of sedation and reduced alertness is officially documented to increase when co-administered with alcohol or other central nervous system depressants due to pharmacodynamic synergism.
  • Population-Specific: Specific patient populations, such as those classified as CYP2D6 poor metabolizers, exhibit altered clearance, which is a consideration for dose restrictions detailed in official guidance.

Mechanism of Action

How Ipimo Works

Ipimo's primary mechanism is defined by antagonistic blockade with high binding affinity of central Dopamine D2 and D3 receptors. This molecular interaction prevents the body’s natural dopamine from initiating postsynaptic signaling, targeting the dopaminergic pathways that regulate motor control, particularly those in the basal ganglia. By dampening the output of overactive neuronal circuits, this action results in a reduction of excessive movement-related signaling and produces a modulated state of motor output.

The molecule also exhibits secondary mechanistic activity through moderate-to-low affinity antagonism at Serotonin 5-HT7 and alpha1-adrenergic receptors, which results in generalized modulation of central nervous system activity. Critically, a separate off-target mechanism involves the inhibition of the KCNH2 potassium ion channel (IKr), which is vital for cardiac electrical function. This inhibition of outward K^+ current leads directly to a prolongation of the electrical repolarization phase of the ventricular action potential, representing a fundamental, mechanism-derived limitation on systemic exposure.

Dosage and Administration Information

Ipimo is administered exclusively via the oral route as a tablet and is typically taken once daily, though the total dose may be administered in divided amounts. A key principle of use is administering the lowest effective dose to manage symptoms.


Standard Dosing and Titration

For adults, treatment typically begins with a daily dose of 1 mg to 2 mg. Dose adjustments are designed to be gradual, with increases occurring no more often than every other day until the appropriate response is observed. The prescribed dose should not exceed the established maximum daily limit of 10 mg.

Specific Administration Conditions

Ipimo tablets can be taken independent of mealtimes, meaning they may be administered with or without food. However, a specific administration constraint requires the avoidance of grapefruit and grapefruit juice, as these can interfere with the metabolism of the drug.

Population-Based Use and Discontinuation

Dosing rules are defined for specific patient groups. For children aged 12 years and older, the initial dose is calculated based on body weight, with the same 10 mg daily limit applying. Patients identified as CYP2D6 poor metabolizers have a distinct restriction, with their dose not permitted to exceed 4 mg per day. For long-term use, the official instruction for discontinuing Ipimo is to utilize a slow down-titration procedure to gradually reduce the dose over time. This procedural requirement structures the entire use protocol from initiation to cessation.

Recent Clinical Evidence

Ipimo: Recent Clinical Evidence


Research Evidence for Severe Chronic Motor and Vocal Tics

Ipimo (Pimozide) was studied for use in patients with severe motor and phonic tics in Tourette's Disorder, especially in research exploring conditions when patients had not adequately responded to standard treatments. The primary evidence is documented in a set of randomized controlled trials (RCTs) and controlled clinical investigations, summarized by subsequent systematic reviews and meta-analyses of these older, pivotal studies.

Research monitored outcomes related to physical discomfort and functional imbalance associated with the tics, primarily using standardized rating scales. In these short-term studies, data describe patterns related to observed scores that were lower in the studied populations when compared to placebo. Studies also explored how Ipimo was associated with changes when compared to other agents, and researchers noted that findings were sometimes mixed or showed no significant difference.


Research Status of Other Indications (Delusional Disorder)

Ipimo was evaluated in a research context for certain profound psychiatric manifestations, historically including the study of delusional disorder. However, the evidence is derived almost entirely from older case reports and observational findings, not from current, rigorous controlled trials. Scientific reviews explicitly highlight the absence of data from randomized controlled trials to support or refute its use for those with delusional disorder, meaning the certainty remains low.


Long-Term Follow-up and Durability of Response

In the research landscape, the limited information for long-term outcomes is noted. The pivotal clinical trials were typically short-term, meaning the duration of follow-up was limited to weeks or a few months. Long-term effects are not fully established, and extended maintenance studies are noted as necessary to fully understand the effects of treatment over many years.


Evidence in Specific Age Groups (Special Populations)

Ipimo was studied for tic reduction in populations that included children, adolescents, and adults. Separate studies were observed in children and adolescents to evaluate tic changes in this younger demographic. While research has explored short-term symptom changes, the results apply only to the populations studied, and data for certain groups remain insufficient.

Key Studies & References

  1. Practice guideline: Treatment of tic disorders and Tourette syndrome

Frequently Asked Questions (FAQ)

Common questions about Ipimo (FAQ)


Q: Is Ipimo used for anything other than its main indication?

The official regulatory documents state that Ipimo is indicated only for the treatment of severe motor and phonic tics associated with Tourette's Disorder. This medicine is generally reserved for patients who have not responded well to other standard treatments. Official labeling restricts its use and notes that it is not indicated for the treatment of tics other than those associated with Tourette's Disorder.


Q: Is Ipimo available in different strengths?

According to the official product information, the active ingredient in Ipimo, Pimozide, is supplied as oral tablets. These tablets are commonly available in 1 mg and 2 mg strengths. Different regions may have varying formulations, but the standard regulated tablets are designed for oral administration.


Q: Does Ipimo interact with common supplements like multivitamins?

Regulatory guidance notes that all substances taken, including non-prescription products like vitamins and herbal remedies, have the potential to interact with Ipimo. Regulatory documents require that patients disclose all medications and supplements to their healthcare provider for interaction review. This allows for checking any potential conflicts that could affect how Ipimo works.


Q: Why are people with [Specific Condition] advised against taking Ipimo?

The restriction on who can use Ipimo is based on the way the drug works in the body. For instance, the drug is strictly contraindicated for individuals with pre-existing heart rhythm issues because the medicine can cause QT prolongation, which affects the heart's electrical system. Similarly, those with liver or kidney issues are contraindicated because the regulatory label notes the risk of impaired clearance, which could lead to excessively high drug levels.


Q: Does Ipimo have a generic version available?

The active component of Ipimo, known as Pimozide, has been approved by regulatory bodies to be sold as a generic medication. Generic versions contain the same active ingredient and are subject to the same strict quality standards as the brand-name product.


Q: How quickly does Ipimo start to show effects?

According to studies of how the drug moves through the body (pharmacokinetics), Ipimo typically reaches its highest concentration in the bloodstream about 6 to 8 hours after being swallowed. However, the time required to observe a noticeable clinical response may be longer than this initial absorption period.


Q: What happens if I miss a dose of Ipimo?

Official regulatory guidance requires that the prescriber provide specific instructions for a missed dose. Patients must consult the directions given by their healthcare provider or the package insert for guidance, as individualized instructions are necessary. This ensures the necessary steps are taken, rather than attempting to self-compensate with a double dose.


Q: How long does Ipimo stay in your system?

Ipimo has a relatively long elimination time from the body. Regulatory documents describe its half-life—the time it takes for half the drug to be eliminated—as averaging around 55 hours (about two to three days). This duration indicates that the medicine remains present in the system for an extended period.


Q: What kind of studies were done before Ipimo was approved?

The regulatory approval was based on clinical studies demonstrating its ability to reduce tic severity compared to placebo in controlled settings. These studies focused specifically on patients with severe tics who had not responded adequately to other standard treatments, establishing its role in the treatment sequence.


Q: Is there a risk of becoming dependent on Ipimo?

Based on its regulatory classification, the active ingredient in Ipimo is considered to have a low potential for abuse or physical dependence. Its classification as a legend drug is used by regulatory bodies to indicate a controlled risk level for misuse or addiction.


Q: What is the general success rate reported in clinical trials for Ipimo?

Clinical trial reports indicate that patients experienced lower tic severity scores when taking the medicine compared to patients on placebo. However, the official regulatory summaries of this research do not define or publish a single, universal success rate percentage for the medicine.


Q: Is it safe to drive while taking Ipimo?

Official warnings state that Ipimo may cause side effects such as drowsiness, dizziness, and blurred vision. The regulatory label includes a specific warning that patients should not drive, operate complex machinery, or participate in hazardous activities until they are certain the medication does not impair their ability to function.


Q: Is there a specific patient group Ipimo works best for?

The official regulatory status defines a very specific patient group for Ipimo's use. It is designated as a treatment reserved only for people with severe tics associated with Tourette's Disorder whose symptoms have not adequately responded to other available medications. Its place in therapy is defined by this restriction.


Q: Does Ipimo affect sleep?

Official reports from clinical studies indicate that Ipimo can be associated with changes in sleep patterns. Side effects reported include both increased drowsiness or sleepiness—particularly in children—and the opposite effect, insomnia (difficulty falling or staying asleep).


Q: Can I take Ibuprofen or Tylenol while on Ipimo?

Official drug interaction data includes a mention of Acetaminophen, an ingredient in Tylenol, which may potentially affect how the body processes Ipimo. Regulatory information advises that patients must consult with their healthcare provider prior to co-administering any non-prescription medications, including common pain relievers.


Q: What is the official status/advice regarding use in pregnancy?

Official documents indicate that controlled studies of Ipimo use in pregnant women have not been conducted. Regulatory documents state that use during pregnancy requires a careful evaluation by a healthcare professional, with the potential benefit weighed against the known risks. Neonates whose mothers used the drug during the third trimester may be born with a risk of extrapyramidal or withdrawal symptoms.


Q: Can I take Ipimo if I have high blood pressure?

Regulatory information notes that changes in blood pressure, including both increases and decreases, have been reported as side effects of the medicine. However, high blood pressure (hypertension) itself is not listed as a specific contraindication. The regulatory label advises that blood pressure should be monitored as directed by a healthcare professional.


Q: What is the expected follow-up routine while using Ipimo?

Regulatory labeling requires specific monitoring for patients using this medicine. This typically includes an Electrocardiogram (ECG)—a test of heart activity—before starting and periodically throughout treatment, particularly when the dose is changed. Periodic monitoring of blood counts and electrolyte levels may also be recommended by a healthcare professional.


Q: Does Ipimo interact with birth control pills?

Ipimo is known to affect hormone levels, specifically by increasing prolactin, which can cause menstrual irregularities (like missed or irregular periods). Due to potential hormonal effects, regulatory information advises consulting with a healthcare provider regarding contraceptive options and any menstrual concerns.


Q: Is Ipimo considered a common treatment?

The official position in the treatment hierarchy defines Ipimo as not a first-line therapy. It is generally reserved for use as a drug of last resort for patients who have severe tics associated with Tourette's Disorder and have not found relief with other available medications.


Q: Are the side effects of Ipimo permanent?

Official warnings state that some serious, involuntary movement-related side effects, such as Tardive Dyskinesia, could become permanent if they occur. The risk of developing these persistent issues is noted to be associated with taking the medicine for a long time or at high doses.


Q: Does Ipimo affect hormone levels?

Yes, the medicine is known to affect the endocrine system. The dopamine-blocking action of the drug can result in increased levels of the hormone prolactin (hyperprolactinemia). This hormonal change may lead to side effects such as changes in the menstrual cycle, breast swelling, or decreased libido.


Q: Are there any known interactions between Ipimo and herbal remedies?

Official patient information requires that the healthcare professional be made aware of all substances being taken, including herbal remedies and non-prescription products. This is because herbal products have the potential to interact with Ipimo and alter how it is processed by the body.


Q: Does Ipimo cause any changes to skin or hair?

Regulatory documents list several dermatologic side effects reported in patients using the medicine. These include changes such as skin discoloration, a general rash, or increased sweating (known as hyperhidrosis).


Q: Is Ipimo a biologic drug?

No, Ipimo is classified as a synthetic chemical substance, not a biologic drug. Its active component is a complex molecule known chemically as a diphenylbutylpiperidine derivative, placing it in the pharmacological class of First-Generation Antipsychotics.

How should Ipimo be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory documents define the mandatory conditions for storing and disposing of Ipimo to maintain its stability and effectiveness.

Storage Category Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Handling Protect from freezing and excessive heat. Keep in the original, tightly closed container.
Environmental Protection Protect the medicine from light and excessive moisture.
Child Safety Keep Ipimo out of the reach of children.
Disposal Do not dispose of unused or expired medicine in household trash or down a drain. Use an official pharmaceutical take-back program or follow instructions from a pharmacist for proper disposal.

These specific storage constraints and disposal rules are based solely on the official product labeling and documentation.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ipimo found in:

A-Z Index: